Ruxolitinib Treatment in an Infant with JAK2+ Polycythaemia Vera-Associated Budd-Chiari Syndrome

Budd-Chiari syndrome is caused by hepatic venous outflow obstruction commonly seen with myeloproliferative neoplasms. Treatment with modified ruxolitinib has been effective for almost 20 months with a good response and no side effects.

 BMJ Case Rep

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.